Matinas BioPharma Holdings, Inc. financial data

Symbol
MTNB on NYSE
Industry
Pharmaceutical Preparations
Location
1545 Route 206 South, Suite 302, Bedminster, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 597 % -34.1%
Debt-to-equity 30 % +40.8%
Return On Equity -121 % -97.8%
Return On Assets -92.7 % -84.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 251M shares +15.4%
Common Stock, Shares, Outstanding 251M shares +15.4%
Entity Public Float 75.9M USD -53.9%
Common Stock, Value, Issued 25K USD +13.6%
Weighted Average Number of Shares Outstanding, Basic 249M shares +14.8%
Weighted Average Number of Shares Outstanding, Diluted 249M shares +14.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.1M USD
Research and Development Expense 13.8M USD -8.77%
General and Administrative Expense 9.99M USD -7.61%
Costs and Expenses 23.8M USD -8.29%
Operating Income (Loss) -23.8M USD -4.73%
Net Income (Loss) Attributable to Parent -22.9M USD -10.9%
Earnings Per Share, Basic -0.1 USD/shares 0%
Earnings Per Share, Diluted -0.1 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.22M USD -56.7%
Marketable Securities, Current 10.1M USD -20.9%
Assets, Current 15.3M USD -36.3%
Property, Plant and Equipment, Net 1.74M USD -17.3%
Operating Lease, Right-of-Use Asset 2.77M USD -17.2%
Intangible Assets, Net (Excluding Goodwill) 3.02M USD 0%
Goodwill 1.34M USD 0%
Assets 24.4M USD -28.4%
Accounts Payable, Current 238K USD -60.6%
Employee-related Liabilities, Current 510K USD +5.81%
Accrued Liabilities, Current 1.44M USD +5.1%
Contract with Customer, Liability, Current 721K USD
Liabilities, Current 2.39M USD -7.61%
Deferred Income Tax Liabilities, Net 341K USD 0%
Operating Lease, Liability, Noncurrent 2.51M USD -22%
Liabilities 5.26M USD -14.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -51K USD +90.1%
Retained Earnings (Accumulated Deficit) -187M USD -14%
Stockholders' Equity Attributable to Parent 19.1M USD -31.4%
Liabilities and Equity 24.4M USD -28.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.77M USD -41.2%
Net Cash Provided by (Used in) Financing Activities 53K USD
Net Cash Provided by (Used in) Investing Activities 2M USD -33.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 251M shares +15.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.72M USD -241%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.99M USD -69.4%
Deferred Tax Assets, Valuation Allowance 40.8M USD +18.7%
Deferred Tax Assets, Gross 40.5M USD +18.9%
Operating Lease, Liability 3.22M USD -15.9%
Payments to Acquire Property, Plant, and Equipment 545K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.4M USD -9.89%
Lessee, Operating Lease, Liability, to be Paid 3.88M USD -19.4%
Property, Plant and Equipment, Gross 3.62M USD -1.2%
Operating Lease, Liability, Current 707K USD +16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.04M USD +4.21%
Lessee, Operating Lease, Liability, to be Paid, Year One 998K USD +4.39%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 659K USD -33.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 944K USD -9.23%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 273K USD -71.1%
Additional Paid in Capital 206M USD +7.11%
Depreciation, Depletion and Amortization 94K USD +1.08%
Share-based Payment Arrangement, Expense 1.41M USD +33.2%